Listen Ventures

Lightstone Ventures is a Boston-based seed and Series A healthcare and biopharmaceutical venture capital firm focused on early-stage investments in drug discovery, clinical-stage therapeutics, and biotech companies developing innovative treatments for serious diseases. The firm invests with initial checks from $3 million to $15 million and takes active board roles, working closely with founding management teams on clinical strategy, regulatory navigation, and partnership development with major pharmaceutical companies. Portfolio companies include BioNano Genomics, the optical genome mapping and genomic analysis company; Karuna Therapeutics, the clinical-stage biopharmaceutical company developing treatments for schizophrenia that was acquired by Bristol-Myers Squibb for $14 billion in 2024; Milestone Scientific, a medical device company; and Protagonist Therapeutics, the clinical-stage company developing peptide-based drugs. Beyond its original investments, the portfolio includes additional early-stage biopharmaceutical and biotech companies.